Navigation Links
ChromaDex® Announces Financial Results for the Year Ended 2011

IRVINE, Calif., March 15, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced financial results for the fiscal year ended December 31, 2011. ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles (GAAP) of approximately $8.1 million and a net loss attributable to common stockholders of $0.12 per share for the fiscal year ended December 31, 2011. As of December 31, 2011, cash, cash equivalents and marketable securities totaled over $420,000. Subsequent to the fiscal year ended December 31, 2011, ChromaDex raised capital of approximately $10.1 million in net proceeds through the sale of its common stock.


"Going into 2012, we are now poised to leverage our product and service offerings related to BluScience™, pTeroPure® and other novel ingredients. Our goal is to build ChromaDex into a leader in the natural products industry," said Jeffrey Himmel, CEO of ChromaDex.

"2011 was truly a landmark year for ChromaDex as the company launched its new dietary supplement product line, BluScience, into the market. Initial distribution of our BluScience products was achieved at a major drug chain and health food store as well as an online retailer. This was the first step in the BluScience national mass-market roll out plan," said Debra Heim, COO and President of the Consumer Products Division of ChromaDex.

Additional Financial Results & NotesChromaDex recorded revenue of $8,112,610 during the year of 2011 as compared to $7,566,370 in 2010, representing year on year growth of 7 percent. The net loss attributable to common stockholders for the fiscal year ended December 31, 2011, was $7,894,984 as compared to a net loss of $2,051,676 in 2010. The net loss in the year of 2011 was largely impacted by an increase in non-cash, share-based compensation expense related to the stock options that were granted following the May 20, 2010 private placement and other non-cash compensation. The effect of this increase, which is a "non-GAAP measure," decreased the net loss for the year of 2011 by $2,969,150 and decreased the loss per share for the year of 2011 by $0.04.

About ChromaDex®:ChromaDex, Inc., a wholly owned and operated subsidiary of ChromaDex, is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex, Inc. has an expanding pipeline of new ingredients, including its pTeroPure® ( pterostilbene for which it has worldwide, exclusive patent pending rights. ChromaDex recently launched its BluScience™ ( line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit or call 949-600-9694.

Forward-Looking Statements:Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in ChromaDex's filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and ChromaDex does not undertake any obligation to update forward-looking statements. ChromaDex intends that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, President

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO
jsh@chromadex.comChromaDex Corporation and SubsidiariesConsolidated Statements of OperationsYears Ended December 31, 2011 and January 1, 201120112010Sales

8,112,610   $
7,566,370   Cost of sales5,640,791   4,621,525   Gross profit2,471,819   2,944,845   Operating expenses:Sales and marketing2,539,252   ,085,510   General and administrative7,796,806   3,876,488   Operating expenses,336,058   4,961,998   Operating loss(7,864,239)  (2,017,153)  Nonoperating income (expenses):Interest income,397   ,545   Interest expense(32,142)  (36,068)  Nonoperating expenses(30,745)  (34,523)  Net loss $
(7,894,984)   $
(2,051,676)  Basic and Diluted loss per common share

(0.12)   $
(0.04)  Basic and Diluted weighted average common shares outstanding8,306,812   48,251,930   Quantitative reconciliation of the differences between the non-GAAP measure and the associated comparable GAAP measureConsolidated Statements of Operations (US GAAP)Effects of Non-cash Charges associated with Consolidated Statements of Operations Share-based Compensation ExpenseExcluding Share-based Compensation (Non-GAAP Presentation) Years Ended December 31, 2011 and January 1, 2011Years Ended December 31, 2011 and January 1, 2011Years Ended December 31, 2011 and January 1, 2201120102011201020112010Sales

$  8,112,610$  7,566,370Sales


$  8,112,610$  7,566,370Cost of sales

5,640,7914,621,525Cost of sales

--Cost of sales

5,640,7914,621,525Gross profit2,471,8192,944,845Gross profit--Gross profit2,471,8192,944,845Operating expenses:Operating expenses:Operating expenses:Sales and marketing

2,539,2521,085,510Sales and marketing

--Sales and marketing

2,539,2521,085,510General and administrative

7,796,8063,876,488General and administrative

(2,969,150)(1,262,071)General and administrative

4,827,6562,614,417Operating expenses10,336,0584,961,998Operating expenses(2,969,150)(1,262,071)Operating expenses7,366,9083,699,927Operating loss (7,864,239)(2,017,153)Operating income2,969,1501,262,071Operating loss (4,895,089)(755,082)Nonoperating income (expenses):Nonoperating income:Nonoperating income (expenses):Interest income

1,3971,545Interest income

--Interest income

1,3971,545Interest expense

(32,142)(36,068)Interest expense

--Interest expense

(32,142)(36,068)Nonoperating expense(30,745)(34,523)Nonoperating income--Nonoperating expense(30,745)(34,523)Net loss$(7,894,984)$(2,051,676)Net income$  2,969,150$  1,262,071Net loss$(4,925,834)$   (789,605)Basic and Diluted loss per common share

(0.04)Basic and Diluted income per common share

.03Basic and Diluted loss per common share

(0.02)Basic and Diluted weightedBasic and Diluted weightedBasic and Diluted weighted  average common shares outstanding

68,306,81248,251,930  average common shares outstanding

68,306,81248,251,930  average common shares outstanding


SOURCE ChromaDex
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson
2. ChromaDex® Announces Management Changes
3. ChromaDex® Names Debra Heim as COO
4. NIAID announces 25 new awards to develop radiation countermeasures
5. Aware Announces Q3 2008 Earnings Conference Call
6. Governor Doyle announces historic genomic research collaboration
7. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
8. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
9. Parkinsons Disease Foundation announces award of $150,000
10. Jefferson Department of Surgery announces new pancreas tumor registry
11. NAS announces initiative to connect entertainment industry with top experts
Post Your Comments:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
Breaking Biology Technology: